What are the indications, dosing regimen, contraindications, adverse effects, and monitoring recommendations for midodrine tablets in adults with symptomatic orthostatic hypotension?

Midodrine for Orthostatic Hypotension

Indication

Midodrine is FDA-approved specifically for symptomatic orthostatic hypotension and represents the only medication with this precise indication. 1, 2 The therapeutic goal is to minimize postural symptoms—not to restore normotension—and treatment should be continued only in patients who demonstrate symptomatic improvement during initial therapy. 1, 3

Diagnostic Confirmation Required

• Orthostatic hypotension is defined as a sustained drop of ≥20 mmHg systolic or ≥10 mmHg diastolic within 3 minutes of standing from a supine position. 2
• Measure blood pressure after 5 minutes of lying/sitting, then at 1 and 3 minutes after standing to document orthostatic changes. 1
• In diabetic patients aged >50 years with orthostatic hypotension, evaluate for cardiovascular autonomic neuropathy using cardiac autonomic reflex tests, as this represents advanced autonomic failure and confers additional mortality risk. 1

---

Dosing Regimen

Start midodrine at 2.5–5 mg three times daily, taken at approximately 4-hour intervals during daytime hours when the patient needs to be upright and active. 1 The dose can be titrated up to 10 mg three times daily based on patient response and tolerability. 1, 2

Critical Timing Considerations

• The last dose must be taken at least 3–4 hours before bedtime (not later than 6 PM) to prevent supine hypertension during sleep. 1
• Doses should be spaced approximately 4 hours apart during waking hours when upright posture is required. 2

Hepatic Impairment

• In patients with liver disease, initiate at the lower end of the dosing range (2.5 mg three times daily) and adjust based on clinical response, as the FDA label does not provide specific hepatic dose adjustments. 1

Special Population: Hemodialysis Patients

• Midodrine is effectively cleared by hemodialysis with a half-life reduced to 1.4 hours. 2
• A single 5 mg dose administered 30 minutes before dialysis improves intradialytic and postdialytic blood pressure. 2

---

Mechanism and Expected Response

Midodrine is a prodrug that undergoes enzymatic hydrolysis to desglymidodrine, a selective alpha-1 adrenergic agonist that increases vasomotor and venomotor tone. 4, 5 It has minimal cardiac and central nervous system effects due to its specificity for peripheral alpha-receptors and poor blood-brain barrier penetration. 2

Clinical Efficacy

• Midodrine increases standing systolic blood pressure by 15–30 mmHg for 2–3 hours, with peak effect at 1 hour post-dose. 1
• At the 10 mg dose, standing systolic blood pressure increases by 22 mmHg (28% improvement, p<0.001 versus placebo). 6
• Midodrine significantly improves symptoms including dizziness/lightheadedness, weakness/fatigue, syncope, low energy level, and impaired ability to stand. 6, 7
• In tilt-table studies, midodrine extends time to syncopal symptoms by 521 seconds compared to placebo (p=0.0131). 8

---

Contraindications and Precautions

Absolute Contraindications

• Active heart failure or significant cardiac dysfunction (avoid fludrocortisone in these patients as well). 1
• Severe supine hypertension. 1

Use with Caution

• Congestive heart failure and concurrent use with other negative chronotropic agents (beta-blockers, digoxin, non-dihydropyridine calcium channel blockers). 2
• Concomitant use with other alpha-adrenergic agents should be avoided, as this may aggravate supine hypertension. 2
• Midodrine can antagonize alpha-adrenergic blockers (terazosin, prazosin, doxazosin) and may result in urinary retention. 2

---

Adverse Effects

Common Side Effects (Mild to Moderate)

• Piloerection (goosebumps) is the most common side effect, reported in 13.5% of patients. 2, 6
• Scalp pruritus/tingling. 6
• Urinary retention or urgency (4% of patients). 2, 6
• Bradycardia and gastrointestinal symptoms. 2
• Chills and paresthesias. 4

Serious Adverse Effect: Supine Hypertension

• Supine hypertension occurs in up to 25% of patients and is the most important limiting factor. 1, 4
• Risk can be reduced by ensuring the last dose is taken at least 4 hours before bedtime. 1, 4
• Elevating the head of the bed by 10 degrees during sleep helps prevent nocturnal polyuria and ameliorate nocturnal hypertension. 1

---

Monitoring Recommendations

Initial and Ongoing Monitoring

• Measure both supine and standing blood pressure at each visit to detect treatment-induced supine hypertension. 1
• Monitor orthostatic vital signs at each follow-up visit. 1
• Reassess the patient within 1–2 weeks after initiating or changing medication doses. 1

Specific Parameters

• Check for urinary retention or urgency regularly. 2
• Monitor for bradycardia and gastrointestinal symptoms. 2
• If combining with fludrocortisone, monitor for supine hypertension, hypokalemia, congestive heart failure, and peripheral edema. 1

---

Non-Pharmacological Adjuncts (Essential for All Patients)

Midodrine should be used in conjunction with non-pharmacological measures, not as monotherapy. 1, 3

Fluid and Salt Management

• Increase fluid intake to 2–3 liters daily unless contraindicated by heart failure. 1, 2
• Increase salt intake to 6–9 grams daily unless contraindicated. 1, 2

Physical Maneuvers and Positioning

• Teach physical counter-pressure maneuvers: leg crossing, squatting, stooping, and muscle tensing during symptomatic episodes (particularly effective in patients <60 years with prodromal symptoms). 1
• Elevate the head of the bed by 10 degrees during sleep. 1, 3
• Advise gradual staged movements with postural changes. 1
• Acute water ingestion of ≥480 mL provides temporary relief with peak effect at 30 minutes. 1

Compression Garments

• Use waist-high compression stockings (30–40 mmHg) and abdominal binders to reduce venous pooling. 1, 2

Dietary Modifications

• Recommend smaller, more frequent meals to reduce postprandial hypotension. 1
• Encourage physical activity and exercise to avoid deconditioning. 1

---

Combination Therapy for Inadequate Response

For patients whose symptoms remain insufficiently controlled with midodrine alone, adding fludrocortisone 0.05–0.1 mg daily is recommended, as the two agents act via complementary mechanisms (alpha-1 adrenergic vasoconstriction versus sodium-retention-mediated volume expansion). 1 Fludrocortisone can be titrated to 0.1–0.3 mg daily based on response. 1

Alternative Agents

• Droxidopa is FDA-approved and particularly effective for neurogenic orthostatic hypotension in Parkinson's disease, pure autonomic failure, and multiple system atrophy. 1, 3
• Pyridostigmine is beneficial for refractory orthostatic hypotension in elderly patients, especially those with concurrent supine hypertension, as it does not worsen supine blood pressure. 1

---

Common Pitfalls to Avoid

• Do not administer midodrine after 6 PM, as this significantly increases the risk of supine hypertension during sleep. 1
• Do not simply reduce the dose of offending medications causing orthostatic hypotension; switch to alternative therapy (e.g., long-acting dihydropyridine calcium channel blockers or RAS inhibitors). 1
• Do not use fludrocortisone in patients with heart failure or supine hypertension. 1
• Do not combine multiple vasodilating agents (ACE inhibitors + calcium channel blockers + diuretics) without careful monitoring. 1
• Do not overlook volume depletion as a contributing factor. 1
• Discontinue or switch medications that worsen orthostatic hypotension (alpha-1 blockers, diuretics, vasodilators) rather than simply reducing doses. 1